$ARKG just broke out after 4 years of accumulation—clean monthly chart showing real impulsive momentum. This is a basket of speculative, high-debt genomic names, which tells you something important: risk appetite is back. You don't get breakouts in bleeding-edge biotech at the start of a recession. This is a late-cycle or early-recovery signal, not a defensive rotation. If you're positioned for hard landing, this kind of price action should make you uncomfortable. Genomics stonks don't rip when credit's tightening and growth is dying.